Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology, 07/03/2012
Kim YH et al. – The combination of carboplatin and pemetrexed was safe and effective in advanced non–squamous non–small–cell lung cancer (NSCLC). Although the sample size was small, the results indicate that pemetrexed is a key drug for advanced non–squamous NSCLC, irrespective of the EGFR mutation status.